Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension

被引：0
|
作者：
Annette S Droste
David Rohde
Mirko Voelkers
Arthur Filusch
Thomas Bruckner
Mathias M Borst
Hugo A Katus
F Joachim Meyer
机构：
[1] Angiology and Respiratory Medicine,Department of Cardiology
[2] Institute for Medical Biometry and Informatics of the University,undefined
来源：
Respiratory Research | / 10卷
关键词：
Bosentan; Systolic Pulmonary Artery Pressure; Idiopathic Pulmonary Arterial Hypertension; Pulmonary Hemodynamic; Expiratory Airflow;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
    Droste, Annette S.
    Rohde, David
    Voelkers, Mirko
    Filusch, Arthur
    Bruckner, Thomas
    Borst, Mathias M.
    Katus, Hugo A.
    Meyer, F. Joachim
    RESPIRATORY RESEARCH, 2009, 10
  • [2] Ambrisentan -: Treatment of pulmonary arterial hypertension endothelin ETA receptor antagonist
    Sorbera, LA
    Castañer, J
    DRUGS OF THE FUTURE, 2005, 30 (08) : 765 - 770
  • [3] Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
    Steiner, M. Kathryn
    Preston, Ioana R.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (05) : 943 - 952
  • [4] Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension
    O'Callaghan, DS
    Gaine, SP
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (04) : 475 - 481
  • [5] Treatment of pulmonary arterial hypertension with macitentan, dual endothelin receptor antagonist
    Bichara, Valentina M.
    Bevacqua, Raul J.
    INSUFICIENCIA CARDIACA, 2019, 14 (03) : 119 - 128
  • [6] Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Kingman, Martha
    Ruggiero, Rosechelle
    Torres, Fernando
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (11) : 1847 - 1858
  • [7] Influence Of Endothelin Receptor Antagonist For The Development Of Thyroid Dysfunction In Patients With Childhood-Onset Pulmonary Arterial Hypertension
    Nakayama, T.
    Takatsuki, S.
    Satoh, M.
    Aso, K.
    Ikehara, S.
    Matsuura, H.
    Saji, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
    Barst, Robyn J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 95 - 109
  • [9] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [10] Sitaxsentan - A new endothelin-receptor antagonist for the treatment of pulmonary arterial hypertension
    Reinhart, Kurt
    White, C. Michael
    FORMULARY, 2007, 42 (05) : 295 - +
12345